Julio Chavez, MD, Moffitt Cancer Center

home / authors / julio-chavez-md-moffitt-cancer-center

Articles

Treatment of R/R DLBCL: Beyond CAR T Therapy

Treatment of R/R DLBCL: Beyond CAR T Therapy

John M. Burke, MD, Rocky Mountain Cancer Centers;Julio Chavez, MD, Moffitt Cancer Center;Nathan H. Fowler, MD, MD Anderson Cancer Center;Grzegorz S. Nowakowski, MD, Mayo Clinic
September 22nd 2020

Read More

Phase 2B SADAL Trial in R/R DLBCL

Phase 2B SADAL Trial in R/R DLBCL

John M. Burke, MD, Rocky Mountain Cancer Centers;Julio Chavez, MD, Moffitt Cancer Center;Nathan H. Fowler, MD, MD Anderson Cancer Center;Grzegorz S. Nowakowski, MD, Mayo Clinic
September 22nd 2020

Read More

RE-MIND Study in R/R DLBCL

RE-MIND Study in R/R DLBCL

John M. Burke, MD, Rocky Mountain Cancer Centers;Julio Chavez, MD, Moffitt Cancer Center;Nathan H. Fowler, MD, MD Anderson Cancer Center;Grzegorz S. Nowakowski, MD, Mayo Clinic
September 22nd 2020

Read More

L-MIND Study in R/R DLBCL

L-MIND Study in R/R DLBCL

John M. Burke, MD, Rocky Mountain Cancer Centers;Julio Chavez, MD, Moffitt Cancer Center;Nathan H. Fowler, MD, MD Anderson Cancer Center;Grzegorz S. Nowakowski, MD, Mayo Clinic
September 22nd 2020

Read More

CAR T in Transplant-Eligible and Transplant-Ineligible DLBCL

CAR T in Transplant-Eligible and Transplant-Ineligible DLBCL

John M. Burke, MD, Rocky Mountain Cancer Centers;Julio Chavez, MD, Moffitt Cancer Center;Nathan H. Fowler, MD, MD Anderson Cancer Center;Grzegorz S. Nowakowski, MD, Mayo Clinic
September 22nd 2020

Read More

Standard of Care for Relapsed/Refractory DLBCL

Standard of Care for Relapsed/Refractory DLBCL

John M. Burke, MD, Rocky Mountain Cancer Centers;Julio Chavez, MD, Moffitt Cancer Center;Nathan H. Fowler, MD, MD Anderson Cancer Center;Grzegorz S. Nowakowski, MD, Mayo Clinic
September 22nd 2020

Read More

Novel Therapies: R2-GDP-GOTEL and Smart Start

Novel Therapies: R2-GDP-GOTEL and Smart Start

Brian Hill, MD, PhD, Cleveland Clinic;Andre Goy, MD, John Theurer Cancer Center;Julio Chavez, MD, Moffitt Cancer Center;Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology
July 17th 2020

Read More

Novel Treatment Combinations for R/R DLBCL

Novel Treatment Combinations for R/R DLBCL

Brian Hill, MD, PhD, Cleveland Clinic;Andre Goy, MD, John Theurer Cancer Center;Julio Chavez, MD, Moffitt Cancer Center;Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology
July 17th 2020

Read More

Relapsed/Refractory DLBCL: Unmet Needs

Relapsed/Refractory DLBCL: Unmet Needs

Brian Hill, MD, PhD, Cleveland Clinic;Andre Goy, MD, John Theurer Cancer Center;Julio Chavez, MD, Moffitt Cancer Center;Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology
July 17th 2020

Read More

Emerging Treatments for Relapsed/Refractory DLBCL

Emerging Treatments for Relapsed/Refractory DLBCL

Brian Hill, MD, PhD, Cleveland Clinic;Andre Goy, MD, John Theurer Cancer Center;Julio Chavez, MD, Moffitt Cancer Center;Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology
July 17th 2020

Read More

SADAL Trial Regimen FDA Approval

SADAL Trial Regimen FDA Approval

Brian Hill, MD, PhD, Cleveland Clinic;Andre Goy, MD, John Theurer Cancer Center;Julio Chavez, MD, Moffitt Cancer Center;Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology
July 17th 2020

Read More

SADAL Trial Overview

SADAL Trial Overview

Brian Hill, MD, PhD, Cleveland Clinic;Andre Goy, MD, John Theurer Cancer Center;Julio Chavez, MD, Moffitt Cancer Center;Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology
July 17th 2020

Read More

CAR T-Cell Therapy Clinical Trials

CAR T-Cell Therapy Clinical Trials

Brian Hill, MD, PhD, Cleveland Clinic;Andre Goy, MD, John Theurer Cancer Center;Julio Chavez, MD, Moffitt Cancer Center;Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology
July 17th 2020

Read More

CAR T-Cell Therapy Response Rates

CAR T-Cell Therapy Response Rates

Brian Hill, MD, PhD, Cleveland Clinic;Andre Goy, MD, John Theurer Cancer Center;Julio Chavez, MD, Moffitt Cancer Center;Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology
July 17th 2020

Read More

CAR T Cell Therapy in Relapsed/Refractory DLBCL

CAR T Cell Therapy in Relapsed/Refractory DLBCL

Brian Hill, MD, PhD, Cleveland Clinic;Andre Goy, MD, John Theurer Cancer Center;Julio Chavez, MD, Moffitt Cancer Center;Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology
July 17th 2020

Read More

Relapsed/Refractory DLBCL Treatment Landscape

Relapsed/Refractory DLBCL Treatment Landscape

Brian Hill, MD, PhD, Cleveland Clinic;Andre Goy, MD, John Theurer Cancer Center;Julio Chavez, MD, Moffitt Cancer Center;Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology
July 17th 2020

Read More

R/R DLBCL: Transplant Eligibility and R-CHOP

R/R DLBCL: Transplant Eligibility and R-CHOP

Brian Hill, MD, PhD, Cleveland Clinic;Andre Goy, MD, John Theurer Cancer Center;Julio Chavez, MD, Moffitt Cancer Center;Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology
July 17th 2020

Read More

Newly Diagnosed DLBCL: Treatment Decision Factors

Newly Diagnosed DLBCL: Treatment Decision Factors

Brian Hill, MD, PhD, Cleveland Clinic;Andre Goy, MD, John Theurer Cancer Center;Julio Chavez, MD, Moffitt Cancer Center;Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology
July 17th 2020

Read More

DLBCL Risk Assessment and Genetic Signatures

DLBCL Risk Assessment and Genetic Signatures

Brian Hill, MD, PhD, Cleveland Clinic;Andre Goy, MD, John Theurer Cancer Center;Julio Chavez, MD, Moffitt Cancer Center;Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology
July 17th 2020

Read More

Therapy Initiation Prior to Cytogenetic Testing Results

Therapy Initiation Prior to Cytogenetic Testing Results

Brian Hill, MD, PhD, Cleveland Clinic;Andre Goy, MD, John Theurer Cancer Center;Julio Chavez, MD, Moffitt Cancer Center;Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology
July 17th 2020

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data